newsfilter
← Latest News
GlobeNewswire·

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

  • BlossomHill Therapeutics aligned with the FDA on a 50 mg twice daily recommended Phase 2 dose for BH-30643 based on favorable pharmacokinetic, safety, and efficacy data.
  • The company announced SOLARA-2, a single-arm pivotal Phase 2 trial with registrational intent for patients with EGFR C797S-positive NSCLC, expecting to dose the first patient in Q1 2027.
  • A collaboration with Foundation Medicine was established to develop a companion diagnostic assay for the EGFR C797S resistance mutation.
  • BlossomHill presented preclinical data on BH-501284, a pseudo-irreversible pan-KRAS inhibitor, showing sustained pathway suppression and durable antitumor activity.
  • An Investigational New Drug (IND) application for BH-501284 is planned for submission in Q1 2027.
  • Translational data validating the mechanism of action for BH-30236 will be presented at the American Society of Hematology Annual Meeting in December.
  • Third quarter 2026 research and development expenses were $21.9 million, an increase from $14.7 million in the same period in 2025.
  • General and administrative expenses for the third quarter of 2026 totaled $3.6 million, up from $2.1 million in the prior year period.
  • The company reported a net loss of $24.0 million for the third quarter of 2026, or $1.29 per share, compared to $16.0 million in the same period in 2025.
  • Cash and cash equivalents totaled $224.9 million as of September 30, 2026, with sufficient funds to support operations into the second quarter of 2028.
  • The company completed its IPO in August 2026, raising $168.3 million in gross proceeds from the sale of 10,516,240 shares.
  • BH-30643 has received Fast Track designation for the C797S resistance population after third-generation EGFR TKI treatment.
  • BH-30236 received orphan drug designation from the FDA for the treatment of acute myeloid leukemia (AML).
Company
BlossomHill Therapeutics, Inc.
Keywords
Nasdaq:BLSM, BlossomHill Therapeutics, Inc.